TY - JOUR
T1 - Clinical Inertia Among Outpatients With Heart Failure
T2 - Application of Treatment Nonintensification Taxonomy to EPIC-HF Trial
AU - Swat, Stanley A.
AU - Helmkamp, Laura J.
AU - Tietbohl, Caroline
AU - Thompson, Jocelyn S.
AU - Fitzgerald, Monica
AU - McIlvennan, Colleen K.
AU - Harger, Geoffrey
AU - Ho, P. Michael
AU - Ahmad, Faraz S.
AU - Ahmad, Tariq
AU - Buttrick, Peter
AU - Allen, Larry A.
N1 - Publisher Copyright:
© 2023 American College of Cardiology Foundation
PY - 2023/11
Y1 - 2023/11
N2 - Background: The contribution of clinical inertia to suboptimal guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) remains unclear. Objectives: This study examined reasons for GDMT nonintensification and characterized clinical inertia. Methods: In this secondary analysis of EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction), a randomized clinical trial evaluating a patient-activation tool on GDMT utilization, we performed a sequential, explanatory mixed-methods study. Reasons for nonintensification among 4 medication classes were assigned according to an expanded published taxonomy using structured chart reviews. Audio transcripts of clinic encounters were analyzed to further characterize nonintensification reasons. Integration occurred during the interpretation phase. Results: Among 292 HFrEF patients who completed a cardiology visit, 185 (63.4%) experienced no treatment intensification, of whom 90 (48.6%) had at least 1 opportunity for intensification of a medication class with no documented contraindication or barriers (ie, clinical inertia). Nonintensification reasons varied by medication class, and included heightened risk of adverse effects (range 18.2%-31.6%), patient nonadherence (range 0.8%-1.1%), patient preferences and beliefs (range 0.6%-0.9%), comanagement with other providers (range 4.6%-5.6%), prioritization of other issues (range 15.6%-31.8%), multiple categories (range 16.5%-22.7%), and clinical inertia (range 22.7%-31.6%). A qualitative analysis of 32 clinic audio recordings demonstrated common characteristics of clinical inertia: 1) clinician review of medication regimens without education or intensification discussions; 2) patient stability as justification for nonintensification; and 3) shorter encounters for nonintensification vs intensification. Conclusions: In this comprehensive study exploring HFrEF prescribing, clinical inertia is a main contributor to nonintensification within an updated taxonomy classification for suboptimal GDMT prescribing. This approach should help target strategies overcoming GDMT underuse.
AB - Background: The contribution of clinical inertia to suboptimal guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) remains unclear. Objectives: This study examined reasons for GDMT nonintensification and characterized clinical inertia. Methods: In this secondary analysis of EPIC-HF (Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction), a randomized clinical trial evaluating a patient-activation tool on GDMT utilization, we performed a sequential, explanatory mixed-methods study. Reasons for nonintensification among 4 medication classes were assigned according to an expanded published taxonomy using structured chart reviews. Audio transcripts of clinic encounters were analyzed to further characterize nonintensification reasons. Integration occurred during the interpretation phase. Results: Among 292 HFrEF patients who completed a cardiology visit, 185 (63.4%) experienced no treatment intensification, of whom 90 (48.6%) had at least 1 opportunity for intensification of a medication class with no documented contraindication or barriers (ie, clinical inertia). Nonintensification reasons varied by medication class, and included heightened risk of adverse effects (range 18.2%-31.6%), patient nonadherence (range 0.8%-1.1%), patient preferences and beliefs (range 0.6%-0.9%), comanagement with other providers (range 4.6%-5.6%), prioritization of other issues (range 15.6%-31.8%), multiple categories (range 16.5%-22.7%), and clinical inertia (range 22.7%-31.6%). A qualitative analysis of 32 clinic audio recordings demonstrated common characteristics of clinical inertia: 1) clinician review of medication regimens without education or intensification discussions; 2) patient stability as justification for nonintensification; and 3) shorter encounters for nonintensification vs intensification. Conclusions: In this comprehensive study exploring HFrEF prescribing, clinical inertia is a main contributor to nonintensification within an updated taxonomy classification for suboptimal GDMT prescribing. This approach should help target strategies overcoming GDMT underuse.
KW - clinical inertia
KW - guideline-directed medical therapy
KW - heart failure with reduced ejection fraction
KW - left ventricular dysfunction
UR - http://www.scopus.com/inward/record.url?scp=85173668819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173668819&partnerID=8YFLogxK
U2 - 10.1016/j.jchf.2023.06.022
DO - 10.1016/j.jchf.2023.06.022
M3 - Article
C2 - 37589610
AN - SCOPUS:85173668819
SN - 2213-1779
VL - 11
SP - 1579
EP - 1591
JO - JACC: Heart Failure
JF - JACC: Heart Failure
IS - 11
ER -